Abstracts tagged "Scleroderma"

Abstract Number: 1066 • 2019 ACR/ARP Annual Meeting
Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis
Christopher Denton ¹, Shiwen Xu ², Sue Verma ³ and Voon Ong⁴, ¹University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ²University College London, London, United Kingdom, ³Leadiant Biosciences, London, United Kingdom, ⁴UCL Medical School, Royal Free Campus, London
Background/Purpose: Altered generation of adenosine from extracellular nucleotides by ectonucleotidases may orchestrate chronic injury responses and promote fibrosis via the adenosine A2A receptor (ADORA2A). We…
Abstract Number: 2590 • 2019 ACR/ARP Annual Meeting
Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis
Anita Chandrasekaran¹, Imran Omar ², Zhicheng Fu ³, Shangping Ren ³ and Monique Hinchcliff ¹, ¹Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³San Diego State University, Department of Computer Science, San Diego, CA
Background/Purpose: Calcinosis cutis, found in both systemic sclerosis (SSc) and juvenile dermatomyositis patients, can be extensive and debilitating. Potential treatments have been identified, but a…
Abstract Number: 728 • 2019 ACR/ARP Annual Meeting
Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases
Yasser Radwan¹, Tina Gunderson ², Cynthia Crowson ³, David Liedl ⁴, Alicia Hinze ¹, Kenneth Warrington ⁴, Paul Wennberg ⁴ and Ashima Makol ¹, ¹Mayo Clinic Minnesota, rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic Rochester, rochester, MN
Background/Purpose: Vasculopathy is a key feature of systemic sclerosis (SSc), a chronic autoimmune disease associated with widespread fibrosis and internal organ dysfunction. While structural abnormalities…
Abstract Number: 1069 • 2019 ACR/ARP Annual Meeting
CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis
Alisa Mueller¹, Andrea Fava ², Deepak Rao ¹ and Francesco Boin ³, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³UCSF, San Francisco, CA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by tissue fibrosis, vascular injury, and autoantibody production. CXCR5+ PD-1+ T follicular helper (Tfh) cells, which…
Abstract Number: 2591 • 2019 ACR/ARP Annual Meeting
Hospitalization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1980-2016)
Caitrin Coffey¹, Avneek Singh Sandhu ², Cynthia Crowson ³, Sara Achenbach ¹, Eric Matteson ⁴, Thomas Osborn ⁵, Kenneth Warrington ⁶ and Ashima Makol ⁵, ¹Mayo Clinic, Rochester, MN, ²kettering health, dayton, OH, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ⁵Mayo Clinic Minnesota, rochester, MN, ⁶Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder associated with multi-organ dysfunction, requiring long-term and multi-disciplinary care. Few studies have estimated the healthcare resource usage…
Abstract Number: 729 • 2019 ACR/ARP Annual Meeting
Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis
Svetlana Nihtyanova¹, Emma Derrett-Smith ¹, Carmen Fonseca ¹, Voon Ong ² and Christopher Denton ³, ¹UCL Medical School, Royal Free Campus, London, United Kingdom, ²UCL Medical School, Royal Free Campus, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: For most patients with diffuse cutaneous systemic sclerosis (dcSSc), skin thickness improves over time, especially with background immunosuppressive treatment. This has reduced confidence in…
Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Aryeh Fischer¹, Oliver Distler ², Dinesh Khanna ³, Yannick Allanore ⁴, Anna Maria Hoffmann-Vold ⁵, Gabriele Valentini ⁶, Toby Maher ⁷, Martin Aringer ⁸, Leslie Meng ⁹, Margarida Alves ¹⁰, Martina Gahlemann ¹¹, Manuel Quaresma ¹⁰ and Masataka Kuwana ¹², ¹University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ⁷National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
Abstract Number: 2595 • 2019 ACR/ARP Annual Meeting
Asymptomatic Scleroderma Antibody Positivity and Progression to Systemic Sclerosis
Derek Jones ¹, Marissa Mangini ¹, Sydney Wearing ¹ and Victoria Shanmugam², ¹The George Washington University School of Medicine and Health Sciences, Washington, DC, ²George Washington University, Georgetown, DC
Background/Purpose: Systemic sclerosis is an autoimmune disease characterized by inflammation, vasculopathy and fibrosis of the skin, vasculature and internal organs along with disease specific autoantibody…
Abstract Number: 730 • 2019 ACR/ARP Annual Meeting
Energy Levels: An Overlooked Element in Patient Assessment in Scleroderma
Yossra Suliman¹, Suzanne Kafaja ², Mohamed Alemam ³ and Daniel Furst ⁴, ¹Rheumatology and Rehabilitation Department. Faculty of Medicine. Assiut University, Assiut, Egypt, ²Department of Medicine. Rheumatology Division. UCLA, Los Angeles, CA, ³Clinical Pathology and Chemistry Department. Qena Faculty of Medicine. South Valley University, Assiut, Egypt, ⁴University of California, Los Angeles, CA
Background/Purpose: Scleroderma (SSc) is a debilitating multi-system chronic disease which directly affects patient related Quality of Life. We wanted to identify how the patient interprets…
Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Maureen Mayes¹, Kristin Highland ², Martina Gahlemann ³, Aryeh Fischer ⁴, Ganesh Raghu ⁵, Mannaig Girard ⁶, Margarida Alves ⁷, Susanne Stowasser ⁷, Jörg Distler ⁸, Marco Matucci-Cerinic ⁹, Elizabeth Volkmann ¹⁰, Masataka Kuwana ¹¹ and Oliver Distler ¹², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁵University of Washington, Seattle, USA, Seattle, ⁶Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ¹⁰University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
Abstract Number: 2607 • 2019 ACR/ARP Annual Meeting
Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis
Robert Fairchild¹, Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ² and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Systemic Sclerosis (SSc) is a progressive fibrotic and vascular disease affecting multiple organs. Calcinosis cutis in SSc is characterized by calcium deposition in the…
Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Voon H. Ong³ and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Daniel Ennis^1,2, Zareen Ahmad³, Keshini Devakandan¹, Melanie A Anderson⁴ and Sindhu Johnson¹, ¹Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network Library Services, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…
Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Rebecca B. Blank¹, Jessica K. Gordon², Jackie Szymonifka³, Shervin Assassi⁴, Elana J. Bernstein⁵, Flavia V. Castelino⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique Hinchcliff⁹, Kate Homer¹⁰, Ami A. Shah¹¹, Victoria Shanmugam¹², Virginia D. Steen¹³, Tracy M. Frech¹⁴ and Dinesh Khanna¹⁵, ¹Internal Medicine, New York Presbyterian-Weill Cornell Hospital, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Rheumatology, Columbia University, New York, NY, ⁶Rheumatology, Harvard Medical School, Boston, MA, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁰Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Rheumatology, The George Washington University, Washington, DC, ¹³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].